Hydroxychloroquine is widely used in rheumatological disease but hepatic side effects have not been reported previously. Two cases are described of fulminant hepatic failure developing after the start of hydroxychloroquine treatment for a chronic rheumatological disorder. In both cases the symptoms of liver disease developed within two weeks of starting hydroxychloroquine and rapidly progressed to fulminant hepatic failure and in neither case was there any pre-existing liver disease. One patient had emergency orthotopic liver transplantation and the other died before a donor organ became available.
Abstract
Hydroxychloroquine is widely used in rheumatological disease but hepatic side effects have not been reported previously. Two Although it is reported that abnormal liver function tests do occur in up to 25% of cases of systemic lupus erythermatosus, in only 8% can they be attributed to the disease itself.5 Hepatic failure has also been described in systemic lupus erythermatosus but in all the reported cases chronic liver disease was established histologically.6 The two cases reported here have histological changes in the liver of an acute massive necrosis with no evidence of chronic disease, entirely consistent with drug related hepatotoxicity.
NSAIDs are a recognised cause of abnormal liver function tests and fulminant hepatic failure3 but the overall incidence of hepatotoxicity is low and results from an idiosyncratic reaction to the drug. This is confirmed in a recent study that suggests that the incidence ofacute liver injury in patients on longterm treatment with NSAIDs is not significantly greater than in subjects who have never used them. 7 The onset of fulminant hepatic failure in these patients so soon after the start of hydroxychloroquine treatment, with histological changes compatible with a drug related cause, implicates this agent as the probable cause. This association is supported further by the fact that although hydroxychloroquine itself has never been reported to cause fulminant hepatic failure, other 4-aminoquinolones have been. This suggests that all members of this group of drugs should be considered as potentially hepatotoxic.
